Boundless Bio
La Jolla
About Boundless Bio
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $251.4M
- Funding stage: IPO
- Last round: Series C (May 2023)
- Ticker: nasdaq:BOLD
- Website: boundlessbio.com
- Phone: 858-766-9912
Industries & Categories
Biotechnology, Health Care, Life Science, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/boundless-bio-79524 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.